Various asset management firms have been adjusting their positions in
Medtronic PLC (MDT). Several have increased their positions, including Generali Asset Management SPA SGR, Synergy Asset Management LLC, Allspring Global Investments Holdings LLC. Conversely, there are firms like Boston Trust Walden Corp, Ethic Inc, and Voya Investment Management LLC which have reduced their holdings. Despite strong Q2 FY2026 results and the presence of growth drivers, some bearish options activities have emerged. Following FDA approval of the company's HUGO System, Stifel has remained neutral on the stock. The company has also announced the filing of an IPO registration for its diabetes business,
MiniMed. MDT's CEO received praises from Jim Cramer of CNBC. Challenges in evaluation are apparent, with some considering the company as overvalued despite indications of an earnings beat. The company has recently closed a public offering of €1.5 billion senior notes. Opinions remain divided on Wall Street, with bullish and bearish views being represented. The company is lauded for its role in creating a recession-proof portfolio and has been identified as a strong momentum and value stock.
Medtronic Plc MDT News Analytics from Sat, 10 May 2025 07:00:00 GMT to Sat, 03 Jan 2026 13:55:25 GMT -
Rating 0
- Innovation -3
- Information 8
- Rumor 4
